Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Recent Patents on Anti-Cancer Drug Discovery

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/157489209787002461PMID 19149686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

  2009cited by this paper
• BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells

  2008cited by this paper
• The Catalogue of Somatic Mutations in Cancer (COSMIC)

  2008cited by this paper
• The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.

  2008cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008cited by this paper
• The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008cited by this paper
• BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results

  2008cited by this paper
• XL518, a potent selective orally bioavailable MEK1 inhibitor, downregulates the RAS/RAF/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in pre-clinical models

  2007cited by this paper
• Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio‐facio‐cutaneous syndrome from Costello syndrome

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

  2007cited by this paper
• Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy

  2007cited by this paper
• The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary

  2007cited by this paper
• RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer

  2007cited by this paper
• Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents

  2007cited by this paper
• Bevacizumab in the treatment of metastatic colorectal cancer.

  2007cited by this paper
• The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice

  2007cited by this paper
• BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation.

  2006cited by this paper
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

  2006cited by this paper
• Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

  2006cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Mechanisms of drug inhibition of signalling molecules

  2006cited by this paper
• Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

  2006cited by this paper
• Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

  2006cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• Regulation and Role of Raf-1/B-Raf Heterodimerization

  2006cited by this paper
• The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.

  2006cited by this paper
• CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations

  2006cited by this paper
• CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models

  2006cited by this paper
• Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

  2005cited by this paper
• SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant

  2004cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• B-RAF is a therapeutic target in melanoma

  2004cited by this paper
• Raf proteins and cancer: B-Raf is identified as a mutational target.

  2003cited by this paper
• BRAF as a potential therapeutic target in melanoma and other malignancies.

  2003cited by this paper
• CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

  2003cited by this paper
• Suppression of BRAF(V599E) in human melanoma abrogates transformation.

  2003cited by this paper
• BRAF mutation in papillary thyroid carcinoma.

  2003cited by this paper
• Mechanisms of regulating the Raf kinase family.

  2003cited by this paper
• Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway*

  2003cited by this paper
• High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• The Raf/MEK/ERK pathway: new concepts of activation

  2001cited by this paper
• Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation*

  2001cited by this paper
• Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases*

  1997cited by this paper

• Integrated Computational and Experimental Insights Into MEK1/2 Inhibitors: Structural Validation, Docking, ADMET, Molecular Dynamics, and Anticancer Evaluation

  2025cites this paper
• SERS‐Guided Precision Resection Combined with Photothermal‐Immunotherapy for Glioblastoma Recurrence Prevention

  2025cites this paper
• Advances in ERK1/2 inhibition: a medicinal chemistry perspective on structure and regulation

  2025cites this paper
• Theranostic Applications of Tailored Lipid-based Nanoparticles as Drug Delivery Systems for Cancer Treatment

  2025cites this paper
• Repurposing of Mebendazole as an Anticancer Agent: A Review

  2025cites this paper
• The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia.

  2024cites this paper
• Novel drug delivery systems for hirudin-based product development and clinical applications.

  2024cites this paper
• Magnetic Ion Channel Activation (MICA)-Enabled Screening Assay: A Dynamic Platform for Remote Activation of Mechanosensitive Ion Channels

  2023cites this paper
• β-eudesmol inhibits cell proliferation and induces ferroptosis via regulating MAPK signaling pathway in breast cancer.

  2023cites this paper
• Dissecting the potential mechanism of antihypertensive effects of RVPSL on spontaneously hypertensive rats via widely targeted kidney metabolomics.

  2022cites this paper
• A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models

  2022cites this paper
• Current insights into the role of BRAF inhibitors in treatment of melanoma.

  2022cites this paper
• Incidence of BRAF V600E Gene Mutation Among Lebanese Population in Melanoma and Colorectal Cancer: A Retrospective Study Between 2010 and 2019

  2022cites this paper
• Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p

  2022cites this paper
• Platelet-derived growth factor-B signalling might promote epithelial-mesenchymal transition in gastric carcinoma cells through activation of the MAPK/ERK pathway

  2021cites this paper
• Role of 4-Thiazolidinone Scaffold in Targeting Variable Biomarkers and Pathways Involving Cancer.

  2021cites this paper
• How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors.

  2021cites this paper
• Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy

  2020cites this paper
• MEK inhibitor resistance mechanisms and recent developments in combination trials.

  2020cites this paper
• Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations

  2020cites this paper
• Role and mechanism of FLNa and UCP2 in the development of cervical cancer

  2020cites this paper
• NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants

  2020cites this paper
• Angelicin—A Furocoumarin Compound With Vast Biological Potential

  2020cites this paper
• Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin Signaling Pathways in Human Cancers

  2020cites this paper
• Histologic, immunohistochemical, and molecular features of pituicytomas and atypical pituicytomas

  2019cites this paper
• JNK-Dependent cJun Phosphorylation Mitigates TGFβ- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses

  2019cites this paper
• RETRACTED: Schizandrin A inhibits proliferation, migration and invasion of thyroid cancer cell line TPC-1 by down regulation of microRNA-429

  2019cites this paper
• LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.

  2019cites this paper
• LINC01127 promotes the development of ovarian tumors by regulating the cell cycle.

  2019cites this paper
• The rearrangement of 1H,1′H-spiro[quinoline-4,2′-quinoxaline]-2,3′ (3H,4′H)-diones – a new and efficient method for the synthesis of 4-(benzimidazol-2-yl)quinolin-2(1H)-ones

  2018cites this paper
• Expression and clinical significance of the RAS / RAF / MAPK cell signaling pathway in gastric cancer

  2018cites this paper
• The genus Polygonatum: A review of ethnopharmacology, phytochemistry and pharmacology.

  2018cites this paper
• Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients

  2018cites this paper
• Cytotoxicity and apoptotic cell death induced by Vitis vinifera peel and seed extracts in A431 skin cancer cells

  2018cites this paper
• Mutation of BRAF V600E in Iraqi Female Patients Diagnosed With Breast Cancer

  2018cites this paper
• Dual or multi-targeting inhibitors: The next generation anticancer agents.

  2018cites this paper
• Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib

  2018cites this paper
• Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.

  2017cites this paper
• RAF-MEK-MAPK Pathway Targeted by Tumor Suppression and Anticancer Therapeutic Agents

  2017cites this paper
• Inhibition of IGF-1 receptor kinase blocks the differentiation into cardiomyocyte-like cells of BMSCs induced by IGF-1

  2017cites this paper
• Aldosterone activates the oncogenic signals ERK1/2 and STAT3 via redox‐regulated mechanisms

  2017cites this paper
• Aldosterone activates the oncogenic signals ERK 1 / 2 and STAT 3 via redox-regulated mechanisms † Running head : Aldosterone activates ERK 1 / 2 and Stat 3

  2017cites this paper
• BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods

  2017cites this paper
• The method for breast cancer grade prediction and pathway analysis based on improved multiple kernel learning

  2017cites this paper
• Current Trends in Cancer Therapy

  2017cites this paper
• ORMDL3 is associated with airway remodeling in asthma via the ERK/MMP-9 pathway

  2017cites this paper
• The in vitro anticancer effects of himachalol from Cedrus Libani. (c2017)

  2017cites this paper
• Revealing the molecular mechanism of different residence times of ERK2 inhibitors via binding free energy calculation and unbinding pathway analysis

  2016cites this paper
• Glabridin arrests cell cycle and inhibits proliferation of hepatocellular carcinoma by suppressing braf/MEK signaling pathway

  2016cites this paper
• Rearrangements of Quinoxalin(on)es for the Synthesis of Benzimidazol(on)es

  2016cites this paper
• Topical delivery of paclitaxel for treatment of skin cancer

  2016cites this paper
• Title New druggable targets in the Ras pathway

  2016cites this paper
• Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients

  2016cites this paper
• Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.

  2016cites this paper
• One-Pot Synthesis of Biheterocycles Based on Indole and Azole Scaffolds Using Tryptamines and 1,2-Diaza-1,3-dienes as Building Blocks†

  2016cites this paper
• Recent advances in the synthesis of benzimidazol(on)es via rearrangements of quinoxalin(on)es

  2016cites this paper
• Biosynthesized Vitis vinifera seed gold nanoparticles induce apoptotic cell death in A431 skin cancer cells

  2016cites this paper
• RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma

  2016cites this paper
• Natural products as modulator of autophagy with potential clinical prospects

  2016cites this paper
• Detection of Apoptosis: From Bench Side to Clinical Practice

  2016cites this paper
• A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors

  2016cites this paper
• Costello Syndrome with Congenital Pulmonary Valve Stenosis and Ventriculomegaly—A Case Report

  2016cites this paper
• The Ras effector NORE1A forms a tumor suppressor complex with BRCA1.

  2015cites this paper
• Anti-cancer chalcones: Structural and molecular target perspectives.

  2015cites this paper
• Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma.

  2015cites this paper
• Photoactivatable Kinase Inhibitors

  2015cites this paper
• Mathematical Models of Tumor Heterogeneity and Drug Resistance

  2015cites this paper
• Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines.

  2015cites this paper
• Adolescent and young adult patients with cancer: a milieu of unique features

  2015cites this paper
• New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond

  2015cites this paper
• The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.

  2015cites this paper
• Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors.

  2015cites this paper
• Molecular Oncologic Testing of Skin and Adnexa Tumors

  2015cites this paper
• Antioxidant and Anticancer Properties of the Extracts from Lepisorus thunbergianus (Kaulf.) Ching

  2015cites this paper
• Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry

  2015cites this paper
• Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26+ cancer stem cells in colorectal carcinoma

  2015cites this paper
• Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.

  2014cites this paper
• Simplifying the complexity of resistance heterogeneity in metastasis.

  2014cites this paper
• Human Epididymis Protein 4 Inhibits Proliferation of Human Ovarian Cancer Cells Via the Mitogen-Activated Protein Kinase and Phosphoinositide 3-Kinase/AKT Pathways

  2014cites this paper
• Computational identification of multi-omic correlates of anticancer therapeutic response

  2014cites this paper
• Potential clinical implications of BRAF mutations in histiocytic proliferations

  2014cites this paper
• Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway

  2014cites this paper
• 3D-QSAR study on 2,3-dihydroimidazo[4,5]-pyridin-2-one derivatives with a meta substitution pattern as V600EBRAF inhibitors

  2014cites this paper
• Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.

  2014cites this paper
• Is Targeted Therapy Feasible in Acute Myelogenous Leukemia?

  2014cites this paper
• A systems biology road map for the discovery of drugs targeting cancer cell metabolism.

  2014cites this paper
• A bismuth diethyldithiocarbamate compound promotes apoptosis in HepG2 carcinoma, cell cycle arrest and inhibits cell invasion through modulation of the NF-κB activation pathway.

  2014cites this paper
• Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

  2014cites this paper
• Tumour Targeting using Radiolabelled Affibody Molecules : Influence of Labelling Chemistry

  2014cites this paper
• In vitro cytotoxicity perspective of diazepinomicin (ECO-4601) on human hepatoma cell line (HEPG2)

  2014cites this paper
• THE ONCOGENIC MAP KINASE SIGNALING PATHWAY MODULATES MHC-I SURFACE EXPRESSION IN MELANOMA

  2014cites this paper
• A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression

  2014cites this paper
• The role of cell density and intratumoral heterogeneity in multidrug resistance.

  2013cites this paper
• Azatyrosinamides: novel RAS-related anticancer agents.

  2013cites this paper
• Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations

  2013cites this paper
• Comparison and validation of genomic predictors for anticancer drug sensitivity.

  2013cites this paper
• A systems biology analysis of autophagy in cancer therapy.

  2013cites this paper
• 3,3-Dimethyl-1H-pyrrolo[3,2-g]quinolin-2(3H)-one derivatives as novel Raf kinase inhibitors

  2013cites this paper
• Use of an ex vivo model of human colorectal tumours to study response to the MEK1/2 inhibitor AZD6244

  2013cites this paper
• Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging

  2013cites this paper